Deubiquitinating enzymes (DUBs) are an emerging drug target class of ~100 proteases that cleave ubiquitin from protein substrates to regulate many cellular processes. A lack of selective chemical probes impedes pharmacologic interrogation of this important gene family. DUBs engage their cognate ligands through a myriad of interactions. We embrace this structural complexity to tailor a chemical diversification strategy for a DUB-focused covalent library. Pairing our library with activity-based protein profiling as a high-density primary screen, we identify selective hits against 23 endogenous DUBs spanning four subfamilies. Optimization of an azetidine hit yields a probe for the understudied DUB VCPIP1 with nanomolar potency and in-family selectivity. Our success in identifying good chemical starting points as well as structure-activity relationships across the gene family from a modest but purpose-build library challenges current paradigms that emphasize ultrahigh throughput in vitro or virtual screens against an ever-increasing scope of chemical space.
CITATION STYLE
Chan, W. C., Liu, X., Magin, R. S., Girardi, N. M., Ficarro, S. B., Hu, W., … Buhrlage, S. J. (2023). Accelerating inhibitor discovery for deubiquitinating enzymes. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-36246-0
Mendeley helps you to discover research relevant for your work.